The PLA2R levels have been clinically used as good biomarkers for evaluating IMN development, progression, and recurrence.
The numbers of circulating [CD14.sup.+][CD163.sup.+][CD206.sup.+] M2 cells were positively correlated with the values of 24 h urinary protein (a), 24 h urinary albumin (b), and serum PLA2R (c), respectively.
A total of 231 paraffin-embedded renal tissue sections from patients with biopsy-proven iMN collected between June 2008 and August 2013 were examined for renal PLA2R expression.
PLA2R was examined in paraffin-embedded sections using rabbit polyclonal anti-PLA2R1 antibodies (Sigma, USA) at a dilution of 1:500 after microwaving at 100% power for a total of 18 min, followed by donkey anti-rabbit FITC IgG (Millipore, USA) at a dilution of 1:100.
Two hundred and thirty-one paraffin-embedded renal tissue sections from patients with histology diagnosis of iMN were tested for PLA2R [Figure 1].
Baseline clinical data at kidney biopsy were available for 186 of these 231 patients, including 145 renal PLA2R positive patients and 41 negative patients as summarized in [Table 1].
A total of 149 patients were followed up for more than 12 months after biopsy, including 128 positive and 21 negative in renal PLA2R staining.
Several studies from Asia investigated presence of PLA2R-Ab and glomerular PLA2R staining.
Analysis of PLA2R-Ab screening during remission showed a limited predictive value to identify PLA2R-related MN, with 8 out of 37 (22%) samples testing positive, whereas PLA2R was found in 22 of 37 (59%) corresponding biopsies .
The respective values for glomerular PLA2R staining were 0.78, 0.91, 34.70, and 0.84 for the same parameters without heterogeneity .
Thus, staining for PLA2R antigen in the kidney should be considered to overcome this limitation.
Secondary Membranous Nephropathy and PLA2R Ab or PLA2R Staining Positivity.
Epitope mapping of the PLA2R
and THSD7A autoantibodies will potentially help to develop immunoabsorption columns to deplete autoantibodies .
30 May 2014 - US FDA said yesterday it had authorised Euroimmun US Inc's Anti- PLA2R
IFA blood test to help identify if membranous glomerulonephritis (MGN), a specific type of kidney disease, is due to the body's rejection of its own kidney tissue or due to another cause.
Future studies using surveillance biopsies and PLA2R
antibodies/antigens may find a predictive model for recurrent disease.